| Role of epidermal growth factor receptor in breast cancer H Masuda, D Zhang, C Bartholomeusz, H Doihara, GN Hortobagyi, ... Breast cancer research and treatment 136, 331-345, 2012 | 761 | 2012 |
| Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial GN Hortobagyi, NT Ueno, W Xia, S Zhang, JK Wolf, JB Putnam, ... Journal of Clinical Oncology 19 (14), 3422-3433, 2001 | 276 | 2001 |
| Targeting the PI3K signaling pathway in cancer therapy C Bartholomeusz, AM Gonzalez-Angulo Expert opinion on therapeutic targets 16 (1), 121-130, 2012 | 245 | 2012 |
| E1A-mediated Paclitaxel Sensitization in HER-2/neu-overexpressing Ovarian Cancer SKOV3.ip1 through Apoptosis Involving the Caspase-3 Pathway NT Ueno, C Bartholomeusz, JL Herrmann, Z Estrov, R Shao, M Andreeff, ... Clinical cancer research 6 (1), 250-259, 2000 | 150 | 2000 |
| High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients C Bartholomeusz, AM Gonzalez-Angulo, P Liu, N Hayashi, A Lluch, ... The oncologist 17 (6), 766-774, 2012 | 148 | 2012 |
| Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt F Yamasaki, MJ Johansen, D Zhang, S Krishnamurthy, E Felix, ... Cancer research 67 (12), 5779-5788, 2007 | 133 | 2007 |
| Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity F Yamasaki, D Zhang, C Bartholomeusz, T Sudo, GN Hortobagyi, ... Molecular cancer therapeutics 6 (8), 2168-2177, 2007 | 96 | 2007 |
| Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells D Zhang, A Pal, WG Bornmann, F Yamasaki, FJ Esteva, GN Hortobagyi, ... Molecular cancer therapeutics 7 (7), 1846-1850, 2008 | 90 | 2008 |
| c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun X Xie, TS Kaoud, R Edupuganti, T Zhang, T Kogawa, Y Zhao, ... Oncogene 36 (18), 2599-2608, 2017 | 86 | 2017 |
| PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival C Bartholomeusz, D Rosen, C Wei, A Kazansky, F Yamasaki, T Takahashi, ... Cancer research 68 (22), 9302-9310, 2008 | 84 | 2008 |
| Systemic Gene Therapy in Human Xenograft Tumor Models by Liposomal Delivery of the E1A Gene NT Ueno, C Bartholomeusz, W Xia, P Anklesaria, EM Bruckheimer, ... Cancer research 62 (22), 6712-6716, 2002 | 84 | 2002 |
| MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model C Bartholomeusz, X Xie, MK Pitner, K Kondo, A Dadbin, J Lee, H Saso, ... Molecular cancer therapeutics 14 (12), 2773-2781, 2015 | 78 | 2015 |
| Antagonism of tumoral prolactin receptor promotes autophagy-related cell death Y Wen, B Zand, B Ozpolat, MJ Szczepanski, C Lu, E Yuca, AR Carroll, ... Cell reports 7 (2), 488-500, 2014 | 59 | 2014 |
| CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells DR Boulbes, GB Chauhan, Q Jin, C Bartholomeusz, FJ Esteva Breast cancer research and treatment 151, 501-513, 2015 | 54 | 2015 |
| A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression J Lee, C Bartholomeusz, O Mansour, J Humphries, GN Hortobagyi, ... Breast cancer research and treatment 146, 259-272, 2014 | 54 | 2014 |
| MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies MK Pitner, JM Taliaferro, KN Dalby, C Bartholomeusz Expert Opinion on Therapeutic Targets 21 (9), 849-859, 2017 | 52 | 2017 |
| EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer X Wang, ME Reyes, D Zhang, Y Funakoshi, AP Trape, Y Gong, T Kogawa, ... Oncotarget 8 (40), 67904, 2017 | 47 | 2017 |
| PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal … C Bartholomeusz, AM Gonzalez-Angulo, A Kazansky, S Krishnamurthy, ... Clinical Cancer Research 16 (6), 1802-1811, 2010 | 44 | 2010 |
| HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer DR Boulbes, ST Arold, GB Chauhan, KV Blachno, N Deng, WC Chang, ... Molecular oncology 9 (3), 586-600, 2015 | 41 | 2015 |
| Gemcitabine overcomes erlotinib resistance in EGFR-overexpressing cancer cells through downregulation of Akt C Bartholomeusz, F Yamasaki, H Saso, K Kurisu, GN Hortobagyi, ... Journal of Cancer 2, 435, 2011 | 37 | 2011 |
